Category: Investment, Biotech, Biodefense Exosomes Sector Heats Up; Aethlon Medical (AEMD), Life Technologies (LIFE) and Eli (LLY) Visit this company: www.aethlonmedical.com New York, NY, Point Roberts, WA - January 3, 2014 (Investorideas.com newswire) Investorideas.com, a global investor news portal issues an exclusive sector snapshot on the rapidly growing exosome market and opportunities for publicly traded companies within the sector. For investors unfamiliar with exosomes, they are cell-derived vesicles that are present in most biological fluids including blood and urine, as well as other body fluids. Because the fluids are easily accessible, they can be used as markers for disease progression. Exosomes are described as tiny, nano-scale bubbles that are released from cells capable of intercellular communication. "Only five years ago the principals of communicating within the body were hormones, immunology or neurology and now we have found another way of communicating and sending genetic signals between cells,” Life Technologies Corp . So why is something so small creating such a huge buzz? Two key significant areas of growth in the sector are diagnostics and therapeutics for diseases such as cancer. Read the full article at Investorideas.com Exosomes; Nano-Scale Bubbles Creating Waves in Diagnostics and Therapeutics How Companies Like Aethlon Medical (AEMD), Life Technologies (LIFE) and Eli Lilly (LLY) (in Partnership with Exosome Diagnostics) are Working with New Forms of Intercellular Communication to Change Personal Medicine as We Know It http://www.investorideas.com/CO/AEMD/news/2013/12171ep.asp Related articles: Invest in Exosomes Before Wall Street Does http://wallstcheatsheet.com/stocks/invest-in-exosomes-before-wall-street-does.html/?ref=YF About Aethlon Medical, Inc. Aethlon Medical creates innovative medical devices to address life-threatening diseases. The Aethlon ADAPT™ (Adaptive Dialysis-like Affinity Platform Technology) establishes the basis for a new class of therapeutics that target the rapid elimination of disease enabling particles from the circulatory system of treated patients. The lead Aethlon ADAPT™ product is the Hemopurifier®, a device that addresses a broad-spectrum of viral pathogens as well as tumor-secreted exosomes that suppress the immune system of cancer patients. Aethlon is also operating under two government contracts with the Defense Advanced Research Projects Agency (DARPA) related the development of a medical device to reduce the incidence of sepsis. Exosome Sciences, Inc. is a majority owned Aethlon subsidiary that is advancing exosome-based strategies to diagnose and monitor cancer and infectious disease progression. Additional information can be found at www.AethlonMedical.com News source: http://www.hispanicbusiness.com/2013/12/4/reports_from_dalian_medical_university_advance.htm About InvestorIdeas.com: InvestorIdeas.com is a global news source for investors following leading business sectors including biotech, tech, mining, mobile, energy, water, defense renewable energy and Latin American stocks. Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas Follow Investorideas.com News on Linkedin.com/today at http://www.linkedin.com/today/investorideas.com Sign up for news alerts: http://www.investorideas.com/Resources/Newsletter.asp Become an Investorideas.com Member http://www.investorideas.com/membership/ Disclaimer/ Disclosure: The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp Disclosure: AEMD compensates Investorideas three thousand per month for news and content publication and distribution BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country. 800-665-0411 - Source - www.Investorideas.com

